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Abstract: Background and Objective: Glucosamine is a safe and common treatment for osteoarthritis. Even so, literature 
data on the cardiovascular safety of glucosamine are limited. The objective of this paper is to investigate the long-term 
effects of crystalline glucosamine sulfate (CGS) on key measures of cardiovascular risk in patients with osteoarthritis. 
Methods: We analyzed safety data from two long-term (6-month and 3-year, respectively) randomized controlled trials of 
CGS. Mean changes in blood pressure, lipids, and glucose were calculated for all patients randomized to CGS or placebo 
in either study and for subgroups with abnormally elevated baseline values. Shift tables were used to analyze transitions 
from normal to abnormal levels, or vice versa. 
Results: This analysis on 428 osteoarthritis patients includes data from subjects who had, on average, high normal blood 
pressure or high cholesterol at baseline. There were no significant changes in mean blood pressure after 6 months on CGS 
(systolic: -5±15 mmHg; diastolic: -5±10 mmHg) or placebo (systolic: -7±14 mmHg; diastolic: -4±10 mmHg). Subgroup 
analysis did not show significant effects in subjects with hypertension. Likewise, blood lipids (total/LDL cholesterol) and 
blood glucose did not change over 3 years and 6 months of treatment, respectively, even in hypercholesterolemic or 
hyperglycemic subjects. The proportions of patients whose blood pressure or cholesterol levels shifted from normal to 
abnormal, or vice versa, were comparable in the CGS and placebo groups. 
Conclusions: Long-term use of CGS did not affect blood pressure, lipids, or glucose in patients with osteoarthritis. These 
findings further support the cardiovascular safety of CGS. 
Keywords: Glucosamine, osteoarthritis, safety, blood pressure, cholesterol, blood glucose. 
INTRODUCTION 
  High blood pressure, high blood cholesterol, and diabetes 
are major risk factors for cardiovascular disease in many 
populations, especially in elderly subjects [1-4]. Clearly, this 
population has a high prevalence of multiple diseases—
including osteoarthritis [5]—that must be managed at the 
same time and often require the use of different drugs. 
Authors from various affiliations have recently stressed the 
importance of evaluating the cardiovascular safety of drugs 
not prescribed for cardiovascular diseases. For instance non-
steroidal anti-inflammatory drugs (NSAIDs), which are 
commonly used by patients with osteoarthritis, can increase 
blood pressure. According to the European guidelines for the 
management of arterial hypertension, medications that can 
raise blood pressure should be monitored carefully [5-7]. 
  Drugs for the treatment of osteoarthritis, the most 
common joint disease in older people, are classified as 
symptom-modifying agents and also as structure-modifying  
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agents if they can delay the progression of joint damage [5, 
8]. Crystalline glucosamine sulfate (CGS; CAS number 
216447-62-0) is a symptom-modifying drug with good 
evidence for favorable long-term effects on disease 
progression. CGS is a well-characterized substance 
containing glucosamine, sulfate, chloride, and sodium ions 
and showing tropism for articular cartilage [9]. It is approved 
as a prescription drug in Europe and elsewhere (Dona
®, 
Viartril-S
® and other trade names of the Rottapharm|Madaus 
Group, Monza, Italy) and is marketed as a branded dietary 
supplement in the US. Extensively studied in randomized 
controlled clinical trials, CGS has a very good safety and 
tolerability profile, similar to that of placebo and 
significantly better than that of reference medications such as 
NSAIDs [10-15]. 
  Among the methods whereby cardiovascular safety is 
assessed in clinical studies, measurements of blood pressure 
and blood lipid levels are regarded as key surrogate markers 
of cardiovascular risk [6]. These variables were not 
prospectively selected for statistical testing in clinical trials 
of CGS, mostly because of the lack of preclinical or clinical 
hints that could relate the use of glucosamine to hypertension 
or hypercholesterolemia. On the other hand, CGS composit-
ion includes a small amount, i.e. 384 mg, of sodium chloride. 70   The Open Rheumatology Journal, 2011, Volume 5  Palma dos Reis et al. 
Its administration adds therefore to the dietary sodium intake 
and might contribute to increase blood pressure levels, 
especially in patients on a controlled sodium diet because of 
their hypertension/high normal blood pressure [7]. It was 
also speculated that glucosamine, which is an amino sugar, 
might lead to hyperglycemia and insulin resistance by over-
activating the hexosamine pathway and impairing GLUT4 
glucose transporter translocation to the plasma membrane 
[16]. Finally, alterations of glucose metabolism and 
dyslipidemia are frequently linked and, although there are no 
other clear mechanisms that may connect glucosamine 
administration with altered lipid metabolism, one report 
described 3 cases of increased cholesterol levels in patients 
receiving a glucosamine-based product [17]. Despite these 
concerns, and probably because glucosamine is traditionally 
regarded as safe, literature data on the cardiovascular safety 
of glucosamine-based products and in particular of the 
original prescription product consisting of CGS, are limited. 
Additional evidence-based references are warranted for a 
safe use of CGS in osteoarthritis patients at risk of 
cardiovascular diseases. 
  The objective of this report is therefore to provide more 
information on the cardiovascular safety of CGS through a 
retrospective analysis of blood pressure, blood lipid, and 
blood glucose data available from two high-quality 
randomized controlled clinical trials. 
MATERIALS AND METHODOLOGY 
  The two clinical trials from which this analysis derives 
were conducted in accordance with the Declaration of 
Helsinki—the latest version available at the time each study 
was designed—and are briefly described below. They were 
approved by the Ethics Committee of each participating 
center, and written informed consent was obtained from each 
patient. Full details on these aspects, as well as on general 
methodology and inclusion/exclusion criteria, are given in 
the original publications by Herrero-Beaumont et al. 
(GUIDE study) and by Reginster et al. [10, 11]. 
Design of the Original Studies 
  Male and female outpatients fulfilling the clinical and 
radiological criteria of the American College of 
Rheumatology for the diagnosis of primary osteoarthritis 
were included in the studies [18]. Both trials were conducted 
according to a prospective, randomized, placebo-controlled 
(and reference-controlled in GUIDE), double-blind design. 
CGS was always used in its once daily formulation, i.e. 
sachets of powder for oral solution, containing 1500 mg of 
glucosamine sulfate. 
  In the GUIDE study (ClinicalTrials.gov identifier: 
NCT00110474) [10], patients with knee osteoarthritis were 
randomized to receive CGS 1500 mg once daily (n=109), 
acetaminophen (paracetamol) 3 g a day (n=109), or matching 
placebo (n=107) for 6 months. In the long-term trial by 
Reginster and his group [11], patients with knee 
osteoarthritis were assigned to receive either CGS 1500 mg 
once daily (n=106) or matching placebo (n=106) for 3 years. 
Methods Relevant to the Present Analysis 
  Repeated blood pressure measurements were available 
from the GUIDE study. They were taken at randomization 
and then after 15 days and 1, 3, and 6 months of double-
blind treatment. Blood pressure was measured on the right 
arm, with the patient in a sitting position after 5 minutes of 
rest. Results are expressed in mmHg. 
  Stored samples from the 3-year trial by Reginster and 
colleagues were used to test whether CGS had an effect on 
blood lipid levels. Blood samples were drawn at enrollment 
in the study and then at the end of each year of treatment. 
Total cholesterol, LDL cholesterol, HDL cholesterol, and 
triglyceride plasma levels were assayed by enzymatic 
techniques, as previously described by other authors [19]. 
All available samples from patients still in the study at each 
time point were assayed. However, because of the technical 
characteristics of the LDL cholesterol assay, slightly fewer 
samples were adequate for direct testing of this parameter. 
Missing LDL cholesterol values were therefore estimated by 
the Friedewald formula (i.e. LDL cholesterol = total 
cholesterol - HDL cholesterol - triglycerides/5) [20]. Data 
are expressed as mg/dL for all blood lipid variables. 
  Measurements of plasma glucose levels were available 
from the GUIDE study, in which fasting glucose 
concentrations were monitored at randomization and after 3 
and 6 months of treatment in all patients still receiving the 
study medications. Plasma glucose was assayed by the 
glucose-oxidase GOD/PAP method (Roche Diagnostics, 
Mannheim, Germany), and data are expressed as mg/dL. 
Statistics 
  For the purposes of this retrospective analysis we took 
into account the data available or obtainable from the 
double-blind period of recent randomized controlled trials of 
CGS. Because the present report is meant to evaluate the 
cardiovascular safety of CGS, all randomized patients were 
included in the Safety Population except for those assigned 
to acetaminophen (paracetamol) in the GUIDE trial. Unless 
otherwise stated, results are reported as mean and standard 
deviation (SD); p values of 0.05 or less are considered 
statistically significant. 
  Regardless of the variable being tested, the primary 
endpoint was the mean absolute change (delta) from baseline 
at each evaluation time point. Statistical comparisons within 
and between groups were performed by one-way analysis of 
variance (ANOVA). No correction for multiple analyses was 
done in order not to miss any safety signal. For descriptive 
purposes, mean absolute values at baseline are reported for 
all available patients. Mean absolute values are also reported 
for patients having an actual measurement both at baseline 
and at the time of assessment. The primary analysis was 
conducted on all available patients from the Safety 
Population of each study. 
  Using the same method as described above, we also did a 
series of secondary analyses to assess the effects of CGS in 
the subgroups of patients who had abnormal blood pressure, 
blood lipid, or blood glucose levels at baseline. Widely 
accepted reference ranges were chosen to establish a cut-off 
between normal and abnormal values. Hypertensive patients 
were defined as those having systolic blood pressure 140 
mmHg and/or diastolic blood pressure 90 mmHg [7]. Total 
cholesterol levels 200 mg/dL or LDL cholesterol levels 
130 mg/dL were considered to be abnormally elevated lipid 
values [21, 22]. Glucose concentrations above the upper Cardiovascular Safety of Glucosamine  The Open Rheumatology Journal, 2011, Volume 5   71 
normal limit (UNL; 110 mg/dL) were regarded as high blood 
glucose levels [23]. These analyses provide a clinically 
meaningful comparison in subgroups of patients who are 
already at risk and might therefore be more susceptible to 
negative changes. 
  Additionally, shift tables were used to evaluate how 
many patients, among those who had their blood pressure or 
blood lipid levels recorded both at baseline and at the end of 
treatment, shifted from normal to abnormal levels (or vice 
versa) following treatment with CGS or placebo. Com-
parison within each treatment group was done by the test of 
McNemar. This analysis provides an assessment of risk by 
taking into account natural fluctuations in measured values. 
RESULTS 
Patient Populations 
  325 and 212 osteoarthritis patients, respectively, were 
enrolled in the two clinical trials that are considered here. Of 
these, 109 were randomized to receive acetaminophen 
(paracetamol) and were therefore excluded from the present 
analysis, the Safety Population of which comprised 428 
individuals overall. Baseline demographic and clinical 
characteristics were comparable between treatment groups in 
each study, as detailed in the original reports [10, 11]. 
Blood Pressure 
  To obtain meaningful information on the cardiovascular 
safety of CGS, we first analyzed blood pressure changes in 
patients who participated in the GUIDE study. On average, 
this population had high normal blood pressure, with no 
differences between treatment groups at baseline. There were 
no significant changes in blood pressure during the 6-month 
study period. However, mean systolic and diastolic values 
tended to decrease over time in both the CGS and the 
placebo groups, as evidenced by the consistent negative sign 
of the change from baseline at each evaluation time point 
(Table 1). 
 
  The shift table shows a similar pattern for CGS and 
placebo. Indeed, the proportion of patients whose blood 
pressure values shifted from normal at baseline to 
hypertensive at the end of treatment (about 7% in each 
group) was outbalanced by a higher proportion of patients 
showing an opposite trend (about 20% in each arm). The 
McNemar test revealed that the subjects who improved were 
significantly more than those who worsened (Table 2). 
  Next, we did a subgroup analysis to find out whether 
CGS had the potential to further impair blood pressure in 
individuals with arterial hypertension. At baseline, 104 
hypertensive subjects were identified in the placebo and 
CGS groups of GUIDE (n=51 and n=53, respectively). 
Paired baseline and 6-month measurements were available 
for 79 such individuals (placebo, n=41; CGS, n=38). Mean 
baseline values for systolic and diastolic blood pressure were 
149±11 and 84±10 mmHg in the placebo group, and 148±10 
and 87±10 mmHg in the CGS arm. In agreement with the 
results observed in the general study population, systolic and 
diastolic blood pressure in hypertensive patients did not 
change significantly but tended to decrease. Mean changes 
were -11±13 and -6±9 mmHg respectively in subjects on 
placebo, and -10±18 and -8±10 mmHg in those on CGS. 
Blood Lipids 
  Secondly, to assess whether long-term exposure to CGS 
could adversely affect cholesterol and triglyceride levels, we 
examined blood lipid changes in subjects who participated in 
the 3-year study by Reginster and his group. At baseline, 
mean total and LDL cholesterol concentrations were above 
the normal range in this population, with no differences 
between treatment groups. No significant changes in total or 
LDL cholesterol were observed during the long-term 
treatment period with placebo or CGS (Table 3). 
  The proportion of patients whose total cholesterol levels 
shifted from normal at baseline to abnormal (high) after 3 
years was comparable in the placebo and CGS groups 
(around 10%). Additionally, it was well balanced by a 
similar proportion of patients with an opposite trend (11.1% 
Table 1.  Systolic and Diastolic Blood Pressure (Expressed in mmHg) During the GUIDE Study 
 
Baseline Values*  Delta at Each Time Point 
Evaluation Time  Study Treatment 
Systolic Diastolic  Systolic  Diastolic 
Placebo (n=107)  136 (16)  78 (11)  -  - 
Baseline 
CGS (n=109)  134 (15)  79 (11)  -  - 
Placebo (n=104)  137 (16)  78 (11)  -2 (12)  -1 (9) 
Day 15 
CGS (n=105)  134 (15)  79 (11)  -3 (13)  -1 (8) 
Placebo (n=97)  136 (16)  78 (11)  -1 (13)  0 (10) 
Month 1 
CGS (n=97)  134 (16)  78 (12)  -2 (11)  -1 (8) 
Placebo (n=92)  137 (16)  78 (11)  -2 (15)  -1 (11) 
Month 3 
CGS (n=93)  134 (16)  78 (12)  -3 (13)  -2 (8) 
Placebo (n=77)  137 (16)  78 (11)  -7 (14)  -4 (10) 
Month 6 
CGS (n=85)  134 (16)  78 (12)  -5 (15)  -5 (10) 
Values are expressed as mean (SD); p=not significant in all comparisons. 
*In this column, the average of absolute values at baseline for the patients still in study at each time point is given. 
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and 14.5% after placebo and CGS, respectively). Likewise, 
no differences were found in the distribution of normal and 
high LDL cholesterol levels between the beginning and the 
end of treatment (Table 4). 
Table 2.  Patients Shifting from Normal to Abnormal (Hypertensive) Blood Pressure Values, and Vice Versa, from Baseline to the 
End of Treatment (Month 6) 
 
Patients on Placebo, n (%) 
Month 6 
 
Normal Abnormal 
Total 
Normal  30 (39.0)  6 (7.8)  36 (46.8) 
Baseline 
Abnormal  17 (22.1)  24 (31.2)  41 (53.2) 
Total  47 (61.0)  30 (39.0)  77 (100) 
p=0.035 
Patients on CGS, n (%) 
Month 6 
 
Normal Abnormal 
Total 
Normal  41 (48.2)  6 (7.1)  47 (55.3) 
Baseline 
Abnormal  18 (21.2)  20 (23.5)  38 (44.7) 
Total  59 (69.4)  26 (30.6)  85 (100) 
p=0.023 
This analysis takes into account patients for whom both values (baseline and 6-month) were available. 
Statistical analysis was done by McNemar test. 
CGS=crystalline glucosamine sulfate. 
 
Table 3.  Total and LDL Cholesterol Levels (Expressed as mg/dL) During the Long-Term Trial by Reginster et al. 
 
Evaluation Time  Study Treatment  Baseline Values*  Values at Each Time Point  Delta at Each Time Point 
Total Cholesterol 
Placebo (n=70)  224 (40)  -  - 
Baseline 
CGS (n=91)  219 (32)  -  - 
Placebo (n=56)  226 (40)  221 (48)  -5 (41) 
Year 1 
CGS (n=77)  219 (33)  223 (33)  4 (33) 
Placebo (n=47)  220 (37)  225 (37)  4 (37) 
Year 2 
CGS (n=66)  219 (32)  222 (35)  3 (31) 
Placebo (n=36)  220 (38)  221 (38)  1 (35) 
Year 3 
CGS (n=62)  216 (30)  216 (35)  0 (37) 
LDL Cholesterol 
Placebo (n=70)  154 (41)  -  - 
Baseline 
CGS (n=92)  161 (34)  -  - 
Placebo (n=56)  155 (40)  153 (39)  -2 (33) 
Year 1 
CGS (n=78)  161 (34)  159 (36)  -3 (32) 
Placebo (n=47)  147 (36)  148 (36)  1 (32) 
Year 2 
CGS (n=66)  161 (33)  161 (35)  -1 (24) 
Placebo (n=36)  147 (38)  140 (34)  -7 (31) 
Year 3 
CGS (n=63)  157 (29)  153 (34)  -5 (31) 
Values are given as mean (SD); p=not significant in all comparisons. 
*In this column, the average of absolute values at baseline for the patients still in study at each yearly clinic visit is given. 
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  Subgroup analysis of individuals with elevated 
cholesterol at baseline substantiated the results observed in 
the general study population. In this trial there were 114 
patients in whom total cholesterol levels were elevated 
before treatment began (49 and 65 in the placebo and CGS 
groups, respectively). Seventy paired baseline and 3-year 
measurements of total cholesterol were available for analysis 
(placebo, n=27; CGS, n=43). Mean baseline values were 
237±27 and 231±21 mg/dL in subjects assigned to placebo 
and CGS, respectively. After 3 years there were no 
significant changes in total cholesterol, which tended to 
decrease in both arms of the study. The average difference 
was -8±34 mg/dL in the placebo subgroup and -9±28 mg/dL 
in the CGS subgroup. Similar results were seen in patients 
who had elevated LDL cholesterol at baseline (126 in total 
and 75 for whom baseline and 3-year measurements were 
available), with no significant changes between or within 
groups. Mean differences between final and baseline LDL 
cholesterol levels were -18±30 and -9±29 mg/dL in the 
placebo and CGS arms, respectively. 
Table 4.  Patients Shifting from Normal to Abnormal (Elevated) Cholesterol Levels, and Vice Versa, from Baseline to the End of 
Treatment (Year 3) 
 
Total Cholesterol 
Patients on Placebo, n (%) 
Year 3 
 
Normal Abnormal 
Total 
Normal  6 (16.7)   3 (8.3)  9 (25.0) 
Baseline 
Abnormal  4 (11.1)  23 (63.9)  27 (75.0) 
Total   10 (27.8)  26 (72.2)  36 (100) 
p=NS 
Patients on CGS, n (%) 
Year 3 
 
Normal Abnormal 
Total 
Normal  12 (19.4)  7 (11.3)  19 (30.6) 
Baseline 
Abnormal  9 (14.5)  34 (54.8)  43 (69.4) 
Total   21 (33.9)  41 (66.1)  62 (100) 
p=NS 
LDL Cholesterol 
Patients on placebo, n (%) 
Year 3 
 
Normal Abnormal 
Total 
Normal  8 (22.2)  4 (11.1)  12 (33.3) 
Baseline 
Abnormal  5 (13.9)  19 (52.8)  24 (66.7) 
Total  13 (36.1)  23 (63.9)  36 (100) 
p=NS 
Patients on CGS, n (%) 
Year 3 
 
Normal Abnormal 
Total 
Normal  7 (11.1)  5 (7.9)  12 (19.0) 
Baseline 
Abnormal  9 (14.3)  42 (66.7)  51 (81.0) 
Total   16 (25.4)  47 (74.6)  63 (100) 
p=NS 
This analysis takes into account patients for whom both values (baseline and 3-year) were available. 
NS=not significant by McNemar test. 
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  On average, patients participating in the Reginster’s trial 
had borderline low HDL cholesterol, which was significantly 
lower in the CGS arm than in the placebo group at baseline. 
Fig. (1) shows that HDL cholesterol tended to increase in 
both groups, although the change was greater in patients on 
CGS than in those on placebo after 1 year (4±7 vs 1±9 
mg/dL; p<0.05) and greater in the placebo group than in the 
CGS arm after 3 years (6±7 vs 2±9 mg/dL; p<0.05). Mean 
triglyceride levels were in the normal range at baseline and 
did not change throughout the 3 years of double-blind 
treatment (Fig. 1). 
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Fig. (1). Baseline levels and changes from baseline for HDL 
cholesterol and triglycerides. Stored blood samples from the 3-year 
trial by Reginster and colleagues were used to test whether GCS 
had an effect on blood lipids. Data are presented as mean ± SD of 
all available measurements. *p<0.05 between groups. 
Blood Glucose 
  Finally, to further confirm that therapeutic doses of CGS 
do not impair glucose metabolism, we analyzed fasting 
glucose changes in subjects who were randomized to receive 
placebo or CGS in the GUIDE study. On average their 
plasma glucose was within the normal range at baseline. 
Table  5 shows that mean plasma glucose levels were 
virtually unaltered between screening and the 3- or 6-month 
assessment in both study groups. 
  Hyperglycemic subjects, i.e. those with plasma glucose 
levels above UNL at baseline, were examined in a separate 
analysis. CGS did not worsen glucose metabolism in this 
subgroup of patients. Rather, their mean glucose levels 
tended to decrease over time (Table 6). As expected, plasma 
glucose levels were unaffected in the subgroup receiving 
placebo. 
DISCUSSION 
  The evidence presented here shows that long-term use of 
crystalline glucosamine sulfate (CGS) in randomized 
controlled trials did not adversely affect blood pressure, 
blood lipids, or blood glucose in patients with osteoarthritis. 
Because changes in these variables are predictors of 
cardiovascular risk [6], the present study provides new 
information supporting the excellent safety profile of CGS. 
  Monitoring the cardiovascular safety of medicines, even 
if they are not intended to treat cardiovascular diseases, is a 
priority going well beyond drug development and approval. 
NSAIDs are a good example of drugs that, while approved 
and widely prescribed for use in osteoarthritis, have been 
found to increase the risk of cardiovascular disease [6, 24]. 
Notably, the European guidelines for the management of 
hypertension include NSAIDs in a list of agents that can 
raise blood pressure. The same guidelines recommend that 
lifestyle changes, including reduction of salt intake, be 
instituted in hypertensive patients and in subjects who have 
high normal blood pressure [7]. Any drug product containing 
sodium salts, therefore, should be evaluated for its potential 
to increase blood pressure. 
  In its once daily formulation, CGS contains 1500 mg of 
glucosamine sulfate and a small amount—384 mg—of 
sodium chloride. This fact must be taken into account by 
patients on a controlled sodium diet but, to date, the effects 
of CGS (or of glucosamine in general) on blood pressure 
have not been assessed systematically. Little information is 
available from the literature. In one cross-sectional study, 
long-term users of multiple dietary supplements, including 
glucosamine, were less likely to have high blood pressure 
than non-users [25]. An experimental study reports that 
systolic blood pressure was lower in normal or hypertensive 
rats treated with glucosamine for 9 weeks than in matching 
control animals [26]. Our present analysis shows that 6 
months of treatment with CGS or placebo did not increase 
systolic or diastolic blood pressure. Rather, their mean 
values tended to decrease both in the general population of 
the GUIDE study and in the subgroup of patients who were 
hypertensive at baseline. Although the proportion of 
hypertensive subjects was significantly lower at month 6 
than at baseline, we do not consider this finding to be 
clinically relevant. Remarkably, patients participating in the 
trial had high normal blood pressure on average, thus falling 
(as a group) within the classes of subjects for whom salt 
intake should be reduced [7]. The study population was 
therefore appropriate for the assessment of potential risks 
induced by treatment with CGS. 
  Likewise, the 3-year Reginster’s trial was considered 
adequate for the evaluation of blood lipid changes after long-
term exposure to CGS. There are no mechanism-based 
literature data supporting a link between glucosamine use 
and hypercholesterolemia. However, we found an article 
reporting 3 cases of increased cholesterol levels in patients 
taking glucosamine, but the author neither considered 
alternative explanations nor provided scientific grounds for a 
causal relationship between the drug and the adverse event 
[17]. Actually, because of the concern raised in that Cardiovascular Safety of Glucosamine  The Open Rheumatology Journal, 2011, Volume 5   75 
publication, other authors did a post-marketing 3-month, 
randomized, double-blind, placebo-controlled study to 
investigate whether glucosamine sulfate could worsen lipid 
metabolism [27]. They concluded that glucosamine sulfate 
does not affect fasting plasma levels of cholesterol (total, 
LDL, and HDL) and triglycerides. Our findings not only 
support such conclusions but also extend them to a much 
longer exposure period and to hypercholesterolemic patients. 
  With regard to “good” cholesterol, although in vitro 
studies have shown that glucosamine stabilizes the mRNA 
for the main protein constituent of HDL (i.e. apoAI) [28], 
CGS did not increase HDL cholesterol in subjects with 
osteoarthritis. On average, HDL values were borderline low 
at baseline and did not change significantly over time. Again 
our results are in line with those obtained by other 
investigators, who demonstrated that glucosamine does not 
have significant effects on lipid profile and glycemic control 
in people with low HDL cholesterol and diabetes [29]. 
  Our data on glucose homeostasis originate from the 
GUIDE trial, in which mean glucose levels were unchanged 
in all groups during the 6-month treatment. We recognize 
that single measures of fasting plasma glucose are far from 
being accurate in predicting the risk of diabetes or 
cardiovascular disease [23]. Yet, the effects of glucosamine 
on glucose metabolism have been studied extensively over 
the past two decades. 
  The concern that exogenous glucosamine might alter 
glycemic control by over-activating the hexosamine pathway 
was raised following experimental studies in which largely 
supra-pharmacological amounts of the compound were given 
intravenously to rats. Under these conditions, glucosamine 
impaired insulin secretion and induced insulin resistance by 
decreasing glucose uptake [16, 30]. Insulin resistance often 
occurs in the hyperglycemic state, is a risk factor for 
diabetes, and is best assessed by euglycemic 
hyperinsulinemic clamp. At least three clinical trials used 
this reference method to examine the effects of oral, intra-
arterial, or intravenous glucosamine [31-33]. At variance 
with experimental models, these studies do not support a role 
for the hexosamine pathway or glucosamine (even at supra-
pharmacological doses) in the regulation of insulin 
sensitivity in humans. A comparison of in vitro data with 
human pharmacokinetic parameters confirms the above 
findings. In cultured L6 muscle cells, glucosamine decreases 
glucose uptake at concentrations higher than 5x10
-3 M [34]. 
When CGS is administered at therapeutic doses, it provides a 
mean maximum plasma concentration (Cmax) of about 9x10
-6 
M [35]. 
  The majority of clinical studies to date, some of which 
included people with type 1 or 2 diabetes, have shown that 
therapeutic doses of glucosamine do not alter glucose 
metabolism in humans [29, 31, 32, 36, 37]. This position has 
been endorsed by recent reviews on the topic [38-40]. But 
we do not want to ignore the few studies hypothesizing that 
glucosamine may affect glucose metabolism, at least in 
subjects with untreated diabetes or glucose intolerance [41, 
42]. Our current findings are reassuring on this point, 
Table 5.  Fasting Plasma Glucose (Expressed as mg/dL) During the GUIDE Study 
 
Evaluation Time  Study Treatment  Baseline Values*  Values at Each Time Point  Delta at Each Time Point 
Placebo (n=100)  99 (14)  -  - 
Baseline 
CGS (n=98)  98 (15)  -  - 
Placebo (n=82)  99 (15)  101 (16)  2 (9) 
Month 3 
CGS (n=77)  97 (15)  97 (15)  0 (9) 
Placebo (n=74)  99 (15)  102 (16)  3 (10) 
Month 6 
CGS (n=76)  98 (15)  98 (15)  0 (9) 
Values are expressed as mean (SD); p=not significant in all comparisons. 
*In this column, the average of absolute values at baseline for the patients still in study at each time point is given. 
CGS=crystalline glucosamine sulfate. 
 
Table 6.  Fasting Plasma Glucose (Expressed as mg/dL) During the GUIDE Study in Patients with Baseline Levels Above the 
Upper Normal Limit (UNL; 110 mg/dL) 
 
Evaluation Time  Study Treatment (n=tot pts; n=pts>UNL)  Values at Each Time Point  Delta at Each Time Point 
Placebo (n=15; n=15)  124 (12)  - 
Baseline 
CGS (n=12; n=12)  129 (17)  - 
Placebo (n=14; n=12)  125 (14)  2 (9) 
Month 3 
CGS (n=10; n=7)  122 (22)  -4 (10) 
Placebo (n=14; n=12)  125 (15)  1 (10) 
Month 6 
CGS (n=10; n=7)  120 (20)  -6 (8) 
Values are expressed as mean (SD); p=not significant in all comparisons. 
n=tot pts: number of patients with an abnormal glucose value at baseline and, of these, number of patients whose glucose levels were available after 3 and 6 months. 
n=pts>UNL: number of patients with a glucose level above UNL at each time point. 76   The Open Rheumatology Journal, 2011, Volume 5  Palma dos Reis et al. 
because blood glucose did not worsen in the subgroup of 
hyperglycemic patients receiving CGS for 6 months. 
However, longitudinal data on diabetic patients are limited, 
and monitoring of blood sugar levels is recommended as a 
precaution when CGS is administered in such individuals. 
  Taken together, our data show that CGS was as safe as 
placebo in randomized controlled trials and did not change 
key markers of cardiovascular health. The analysis presented 
here, like any study, has both strengths and limitations. 
Indeed, this is the first report providing detailed statistics on 
blood pressure levels in osteoarthritis patients, either 
hypertensive or non-hypertensive, during treatment with 
CGS. The main limitation lies in the nature of a retrospective 
analysis. The original studies were designed to show clinical 
efficacy in osteoarthritis—and they did it—but may be 
undersized to detect small changes in the safety variables 
monitored. Still, our findings are consistent with those 
gathered in the last 15 years of post-marketing experience 
and surveillance. In the period between 1995 and 2010, a 
roughly estimated 29 million patients were treated with 
CGS, based on an average 3-month treatment period. By 
combining figures on patient exposure with the Company’s 
global Pharmacovigilance database, containing spontaneous 
Individual Case Safety Reports (ICSRs) collected worldwide 
since 1995, an incidence below 1/1,000,000 is found for the 
terms “increased blood pressure” (n=28), “increased 
cholesterol/lipid levels” (n=03), and “increased glucose” 
(n=18). These figures are obtained including medically-
related terms and using a conservative approach (i.e. all 
ICSRs are taken into consideration regardless of the 
causality relationship with CGS, and even non-medically 
validated reports are included in the calculation). 
CONCLUSION 
  This report provides new evidence supporting the 
cardiovascular safety of CGS in the long-term treatment of 
osteoarthritis. 
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